GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of GeneDx as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 833-538-3615 or via email ([e-mail]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wgs/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 3, 2026.

About the Lawsuit

GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s adjusted gross margins were deteriorating and were on track to fall from 74% to 69%; (ii) the Company was on track to miss its revenue estimates for both its exome and genome product lines; (iii) as a result, the Company would be forced to lower its full year revenue guidance to $475–$490 million, down from $540–$550 million; (iv) the Company’s prior acquisition of Fabric Genomics had not delivered the scalable, recurring revenue-generating platform the Company had touted, resulting in a $31.2 million impairment loss; and (v) as a result of the foregoing, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.

The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn